TrialCancer medicine2020

Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.

Wei Sang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.